MedTrace Logo

Evaluating Serum Sestrin in Leiomyoma Patients

NCT04819633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2021-09-21

No results posted yet for this study

Summary

Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circumstances of DNA damage, hypoxia and oxditive stress and play an important role in autophagia. The aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.

Conditions

  • Uterine Leiomyoma

Interventions

OTHER

Determination of serum sestrin levels

Serum sestrin levels will be determined using venous blood samples obtained from the subjects.

Sponsors & Collaborators

  • Sisli Hamidiye Etfal Training and Research Hospital

    lead OTHER

Principal Investigators

  • Pinar Yalcin Bahat, MD · University of Health Sciences Turkey, Istanbul Kanuni Sultan Suleyman Training and Research Hospital

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-03-01
Completion
2021-04-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04819633 on ClinicalTrials.gov